Study of ONO-1101 in Patients Scheduled for Coronary Angiography
NCT ID: NCT00560209
Last Updated: 2012-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
183 participants
INTERVENTIONAL
2007-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease
NCT00540670
Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)
NCT02956993
YN001-004 in Patients With Coronary Atherosclerosis in Australia
NCT06700720
A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome
NCT00619164
A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men
NCT00551317
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
P
ONO-1101
placebo for 1 minute IV
E2
ONO-1101
0.125 mg/kg for 1 minute IV
E1
ONO-1101
0.06 mg/kg for 1 minute IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ONO-1101
placebo for 1 minute IV
ONO-1101
0.06 mg/kg for 1 minute IV
ONO-1101
0.125 mg/kg for 1 minute IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Heart rate less than 90 beats/min and more than 70 beats/min at entering the CT room
Exclusion Criteria
* Renal failure
* Asthma
* Concomitant beta-receptor blocking agent
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ono Pharmaceutical Co. Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shinichi Kikawa
Role: STUDY_DIRECTOR
Ono Pharmaceutial Co., Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kinki Region
Kinki, , Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jinzaki M, Hirano M, Hara K, Suzuki T, Yamashina A, Ikari Y, Iino M, Yamaguchi T, Kuribayashi S. A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting beta1-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease. Int J Cardiovasc Imaging. 2013 Jun;29 Suppl 1(Suppl 1):7-20. doi: 10.1007/s10554-013-0253-3. Epub 2013 Jun 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ONO-1101-26
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.